GSK3B and Alzheimer disease: We believe this discrepancy may not be controlled simply by GSK3β or PKA but may be due to some regulatory mechanism at many phosphor-Tau sites, such as protein conformational changes which is versatile and possesses many tasks independently during AD pathogenesis (Figure 6).